Summit Therapeutics Inc. (SMMT) Stock Forecast
SMMT analyst forecast
as of October 17, 2026- Analyst consensus
- Buy 4.24 / 5 from 17 analysts
- Price target
- $30.20 average of analyst targets
- Upside to target
- +106.4% from the latest close
- Next earnings
- October 19, 2026 EPS estimate $-0.28
- 52-week range
- $12.43 – $26.38
SMMT analyst ratings
17 analystsNumber of analysts at each rating.
SMMT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SMMT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.21 | −$0.32 | −$0.11 | −$0.23 | +9.7% | 12 |
| Current fiscal year (2026) | −$0.84 | −$1.22 | −$0.50 | −$1.07 | +20.9% | 11 |
| Next fiscal year (2027) | −$0.88 | −$1.23 | −$0.44 | −$0.84 | −4.6% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SMMT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $54,000 | $0 | $379,000 | 0.0% | 14 |
| Current fiscal year (2026) | $2.9M | $0 | $11.3M | 0.0% | 15 |
| Next fiscal year (2027) | $42.0M | $0 | $131.5M | +1,328.4% | 15 |
SMMT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SMMT revenue: reported and forecast
SMMT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.22 | −$0.22 | −$0.21 | −$0.21 | −$0.21 | −4.5% | 1 up · 7 down |
| Current fiscal year (2026) | −$0.82 | −$0.86 | −$0.85 | −$0.85 | −$0.84 | +2.2% | 2 up · 6 down |
| Next fiscal year (2027) | −$0.88 | −$0.89 | −$0.88 | −$0.86 | −$0.88 | +0.1% | 2 up · 6 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SMMT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; SMMT beat in 4 of 11.
What analysts expect from SMMT
17 analysts cover Summit Therapeutics; their consensus rating is buy (4.24 on a 1–5 scale, where 5 is a strong buy). The average price target is $30.20, 106.4% above the latest close of $14.63. Analysts expect earnings of −$0.84 per share for 2026, +20.9% from a year earlier. For 2027 the average estimate is −$0.88 per share on revenue of $42.0 million. Summit Therapeutics beat the EPS estimate in 4 of the last 11 quarters.
Related: SMMT income statement, SMMT key metrics, SMMT chart. See the SMMT stock overview for the latest quote and news.
SMMT forecast FAQ
What is Summit Therapeutics's price target?
The average analyst price target for Summit Therapeutics is $30.20, 106.4% above the latest close of $14.63.
Is Summit Therapeutics a buy, hold or sell?
Of 17 analysts covering Summit Therapeutics, 10 rate it a strong buy, 1 a buy, 6 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Summit Therapeutics's EPS forecast?
Analysts forecast −$0.84 per share for 2026 (range −$1.22 to −$0.50); for 2027 the estimate is −$0.88.
What is Summit Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $2.9 million, growth of 0.0%; for 2027 it is $42.0 million.
When does Summit Therapeutics report earnings?
Summit Therapeutics is expected to report results for the quarter ending September 30, 2026 on October 19, 2026 after the market closes; the EPS estimate is $-0.28.
Does Summit Therapeutics usually beat earnings estimates?
Summit Therapeutics reported EPS at or above the analyst estimate in 4 of the last 11 quarters.